Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SLC18A3 | Q16572 | 3/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.32 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.32 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1371597 | 0.68 | SLC18A3 (0.40) | GAAMAPTSLC18A3SIGMAR1PIM1 | |
| SCHEMBL2013478 | 0.68 | SLC18A3 (0.48) | GAAMAPTSLC18A3SIGMAR1ADRA1A | |
| SCHEMBL8635652 | 0.66 | GAA (0.50) | GAAMAPTSLC18A3SIGMAR1ADRA1A | |
| SCHEMBL4169706 | 0.65 | SLC18A3 (0.42) | GAAMAPTSLC18A3SIGMAR1ADRA1A | |
| SCHEMBL778067 | 0.64 | SLC18A3 (0.44) | GAAMAPTSLC18A3SIGMAR1ADRA1A | |
| Hydrochloric Acid SCHEMBL6997190 | 0.64 | SLC18A3 (0.41) | GAAMAPTSLC18A3SIGMAR1ADRA1A | |
| SCHEMBL8510366 | 0.63 | SLC18A3 (0.48) | GAAMAPTSLC18A3SIGMAR1ADRA1A | |
| SCHEMBL4426335 | 0.63 | SLC18A3 (0.35) | GAAMAPTSLC18A3SIGMAR1ADRA1A | |
| SCHEMBL385172 | 0.63 | SLC18A3 (0.48) | GAAMAPTSLC18A3SIGMAR1AKR1C3 | |
| SCHEMBL4224175 | 0.63 | SLC18A3 (0.43) | GAAMAPTSLC18A3SIGMAR1AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1797892-B1 | Use of modified cyclosporins for the treatment of HCV disorders | NOVARTIS AG (CH) | 2013-10-23 | — | — | EP | disclosed |
| US-7968518-B2 | Use of modified cyclosporins for the treatment of HCV disorders | NOVARTIS AG (CH) | 2011-06-28 | — | — | US | disclosed |
| US-7897565-B2 | Compositions for HCV treatment | NOVARTIS AG (CH) | 2011-03-01 | — | — | US | disclosed |
| US-20100173838-A1 | NOVEL PROCESS FOR THE PREPARATION OF CYCLOSPORIN DERIVATIVES | VISKOV CHRISTIAN | 2010-07-08 | — | — | US | disclosed |
| US-20100130408-A1 | USE OF MODIFIED CYCLOSPORINS | KOHJIMA MOTOYUKI | 2010-05-27 | — | — | US | disclosed |
| US-7678766-B2 | Process for the preparation of cyclosporin derivatives | AVENTIS PHARMA S.A. (FR) | 2010-03-16 | — | — | US | disclosed |
| US-20090214464-A1 | COMPOUNDS FOR FLAVIVIRIDAE TREATMENT | NOVARTIS AG (CH) | 2009-08-27 | — | — | US | disclosed |
| US-20090104149-A1 | Compositions For HCV Treatment | NOVARTIS AG (CH) | 2009-04-23 | — | — | US | disclosed |
| EP-1098903-B1 | METHOD FOR PREPARING CYCLOSPORIN DERIVATIVES | AVENTIS PHARMA SA (FR) | 2008-09-03 | — | — | EP | disclosed |
| US-20070275884-A1 | Use of modified cyclosporins for the treatment of hcv disorders | NOVARTIS AG (CH) | 2007-11-29 | — | — | US | disclosed |
| US-5977067-A | THERAPY FOR RETROVIRUSES INFECTIONS | RHONE-POULENC RORER S.A. (FR) | 1999-11-02 | — | — | US | disclosed |
| EP-0951474-A1 | NOVEL CYCLOSPORIN DERIVATIVES, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Aventis Pharma S.A. (FR) | 1999-10-27 | — | — | EP | disclosed |
| EP-0948527-A1 | CYCLOSPORIN DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Aventis Pharma S.A. (FR) | 1999-10-13 | — | — | EP | disclosed |
| US-5965527-A | CYCLOSPORIN A SULFIDED AT THE 3 POSITION BY R-(CH)N-S-BY REACTING A LITHIUM-ACTIVATED DERIVATIVE WITH THE DISULFIDE; SYNERGISTIC MIXTURE WITH A RETROVIRUS VIRICIDE; SIDE-EFFECT REDUCTION; AIDS AND ARC (AIDS RELATED COMPLEX) | RHONE-POULENC RORER, S.A. (FR) | 1999-10-12 | — | — | US | disclosed |
| WO-1999032512-A1 | NOVEL METHOD FOR PREPARING CYLOSPORIN DERIVATIVES | AVENTIS PHARMA (FR) | 1999-07-01 | — | — | WO | disclosed |
| WO-1998049193-A1 | NOVEL CYCLOSPORIN DERIVATIVES, PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | RHONE-POULENC RORER S.A. (FR) | 1998-11-05 | — | — | WO | disclosed |
| WO-1998028330-A1 | NOVEL CYCLOSPORIN DERIVATIVES, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | RHONE-POULENC RORER S.A. (FR) | 1998-07-02 | — | — | WO | disclosed |
| WO-1998028329-A1 | CYCLOSPORIN DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | RHONE-POULENC RORER S.A. (FR) | 1998-07-02 | — | — | WO | disclosed |
| EP-0545421-A1 | 4-(4-piperidinyl-thieno(3,2-c)pyridine derivatives of N-alkylglutarimides as antipsychotic agents | Bristol-Myers Squibb Company (US) | 1993-06-09 | — | — | EP | disclosed |
| US-5137894-A | Psychological disorders | BRISTOL-MYERS SQUIBB COMPANY A CORPORATION OF DELAWARE | 1992-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130408-A1 | USE OF MODIFIED CYCLOSPORINS | CHP1, SERPINA6, FKBP2 | GAA 1480/4885MAPT 4212/4885SLC18A3 2386/4885 |
| US-20090104149-A1 | Compositions For HCV Treatment | HAVCR2, PPIB, FKBP1B | GAA 1597/4885MAPT 2578/4885SLC18A3 3863/4885 |
| US-20070275884-A1 | Use of modified cyclosporins for the treatment of hcv disorders | HAVCR2, FKBP1A, FKBP2 | GAA 947/4885MAPT 3684/4885SLC18A3 3731/4885 |
| US-20090214464-A1 | COMPOUNDS FOR FLAVIVIRIDAE TREATMENT | HAVCR2, PPIG, PPIH | GAA 861/4885MAPT 2866/4885SLC18A3 3033/4885 |
| US-20100173838-A1 | NOVEL PROCESS FOR THE PREPARATION OF CYCLOSPORIN DERIVATIVES | MGMT, MALT1, CHP1 | GAA 1325/4885MAPT 4440/4885SLC18A3 4067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.